AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) � an open-label extension to the TACTT3 study

The primary objective of the study is the evaluation of the safety and local tolerance of up to 3 quarterly treatment cycles each with 3 repeated doses of AM-101 0.87 mg/mL1 in subjects previously treated in the scope of the TACTT3 study with either AM-101 0.87 mg/mL or placebo.